2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1890

Methotrexate Adverse Events in a Randomized Double-Blind Placebo-Controlled Trial:Results from the Cardiovascular Inflammation Reduction Trial (CIRT)
Abstract Number: 369

Methotrexate and Interstitial Lung Disease in Patients with Inflammatory Articular Disease: A Systematic Review
Abstract Number: 2377

Methotrexate Discontinuation and Dose Decreases After Therapy with Tocilizumab: Results from the Corrona Rheumatoid Arthritis Registry
Abstract Number: 1759

Methotrexate in Patients with Hand Erosive Osteoarthritis Refractory to Usual Treatments: A Randomized, Double-blind, Placebo-controlled Trial
Abstract Number: 2793

Methotrexate Intolerance: A Qualitative Descriptive Study of the Adult Rheumatoid Arthritis Patients’ Perspectives
Abstract Number: 926

Methotrexate Is Associated with Reduced Cardiovascular Risk in Rheumatoid Arthritis Independent of Disease Activity Modification
Abstract Number: 2357

Methotrexate Liver Toxicity in a Large Randomized Controlled Trial
Abstract Number: 2015

Methotrexate Treatment Is Associated with Reduction of Neutrophil Reactive Oxygen Species and CD177 in RA Patients
Abstract Number: 1780

Microbiome in Offspring of Ankylosing Spondylitis Patients
Abstract Number: 961

Microenvironment in Systemic Sclerosis Provides a Protective Niche for Tissue-resident B Cells During B Cell Depletion Therapy with Anti-CD20 Antibody
Abstract Number: 75

Microglia-Specific Transcriptional Signatures Correlate with Behavioral Deficits in ‘Neuropsychiatric Symptoms of Systemic Lupus Erythematosus’
Abstract Number: 2026

MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27
Abstract Number: 966

Minimal Residual Autoimmunity After Rituximab in ANCA-associated Vasculitis Patients
Abstract Number: 2240

Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis
Abstract Number: 2612

Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].